Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
daurinol
- Development stage
- Preclinical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Daurinol is a small molecule natural product classified as an **arylnaphthalene lignan**, first isolated from the medicinal plant Haplophyllum dauricum. It has been investigated primarily for its **potential anticancer properties**, with reported activity including inhibition of DNA topoisomerase II, leading to cytotoxic effects in cancer cells and potential modulation of cell cycle and apoptosis pathways. Mechanistic studies and preclinical evaluations suggest daurinol acts as a topoisomerase II inhibitor, but it is not an approved pharmaceutical and remains in the investigational stage for oncology indications[6].
02
Targets
TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on daurinol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on daurinol.